Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $45.25.
A number of equities analysts have recently issued reports on HOLX shares. Bank of America Corp lowered shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 15th. Piper Jaffray Companies restated an “overweight” rating and set a $51.00 target price on shares of Hologic in a research report on Tuesday, March 14th. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Friday, January 6th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Friday, December 16th. Finally, Canaccord Genuity set a $48.00 target price on shares of Hologic and gave the stock a “buy” rating in a research report on Monday, January 23rd.
Shares of Hologic (NASDAQ:HOLX) traded down 0.52% during midday trading on Monday, reaching $42.37. 520,701 shares of the company traded hands. Hologic has a 1-year low of $32.64 and a 1-year high of $42.97. The stock’s 50-day moving average is $40.69 and its 200-day moving average is $39.23. The stock has a market capitalization of $11.83 billion, a P/E ratio of 36.21 and a beta of 1.10.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 1st. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.01. The business had revenue of $734.40 million for the quarter, compared to analyst estimates of $725.01 million. Hologic had a net margin of 11.57% and a return on equity of 27.17%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.46 earnings per share. Equities analysts predict that Hologic will post $1.93 EPS for the current fiscal year.
In related news, Director Elaine Ullian sold 9,423 shares of the stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $39.54, for a total transaction of $372,585.42. Following the completion of the sale, the director now directly owns 36,798 shares of the company’s stock, valued at $1,454,992.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sally Crawford sold 17,396 shares of the stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $42.00, for a total value of $730,632.00. Following the sale, the director now directly owns 152,305 shares of the company’s stock, valued at $6,396,810. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of the company. Korea Investment CORP increased its stake in shares of Hologic by 58.7% in the third quarter. Korea Investment CORP now owns 112,200 shares of the company’s stock valued at $4,357,000 after buying an additional 41,500 shares in the last quarter. Martingale Asset Management L P increased its stake in Hologic by 23.3% in the fourth quarter. Martingale Asset Management L P now owns 406,802 shares of the company’s stock worth $16,321,000 after buying an additional 76,831 shares during the period. State Treasurer State of Michigan increased its stake in Hologic by 14.8% in the third quarter. State Treasurer State of Michigan now owns 96,800 shares of the company’s stock worth $3,759,000 after buying an additional 12,500 shares during the period. California State Teachers Retirement System increased its stake in Hologic by 0.8% in the third quarter. California State Teachers Retirement System now owns 595,624 shares of the company’s stock worth $23,128,000 after buying an additional 5,000 shares during the period. Finally, Tyers Asset Management LLC acquired a new stake in Hologic during the fourth quarter worth approximately $454,000. 94.09% of the stock is owned by hedge funds and other institutional investors.
Your IP Address:
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.